3×5 Partners
3x5 Partners is a venture capital firm based in Portland, Oregon, founded in 2011. The firm specializes in identifying and investing in innovative companies within the life sciences and resource-driven sectors. Its focus includes businesses that aim to enhance the efficiency of resource consumption, addressing challenges related to energy, food, waste, water, and other natural resources. Additionally, 3x5 Partners seeks opportunities in the life sciences sector to improve patient outcomes through advancements in biopharma and medical devices. The managing directors, Tony Arnerich and Nicholas Walrod, have a track record of guiding over 20 companies through significant milestones and have successfully deployed substantial capital across multiple funds and special purpose vehicles. With a commitment to fostering solutions that can lead to substantial future value, the firm positions itself as a key player in the venture capital landscape.
https://crunchbase.com/organization/***
https://linkedin.com/company/***
18 past transactions
Kaleidoscope
Series A in 2023
Founded in 2016, Kaleidoscope designs, administers, and hosts branded scholarship and grant programs on a cloud-based marketplace. Its platform connects scholarship funders with qualified students, creating personalized, curated opportunities.
Smart Wires
Post in 2022
Founded in 2010, Smart Wires Inc. specializes in manufacturing and distributing modular power flow control products and grid optimization solutions for transmission organizations worldwide. Its solutions enhance grid reliability, facilitate renewable connections, resolve short-term issues, accelerate projects, minimize disruption, mitigate uncertainty, and improve power transfer capacity.
Bonum Therapeutics
Series A in 2022
Bonum Therapeutics is a biotechnology company focused on developing protein-based drugs aimed at treating various diseases, with a primary emphasis on cancer. The company has established a technology platform that enables the creation of drugs capable of sensing their local environment and transitioning from an inactive to an active form. This innovative approach allows for the development of therapeutics that can be tailored to respond to specific conditions, thereby enhancing the potential for effective treatment of diseases that currently lack viable cures. In addition to cancer, Bonum Therapeutics also targets metabolic diseases, immunological disorders, and pain management.
Fervo Energy
Series C in 2022
Founded in 2017, Fervo Energy specializes in developing and operating geothermal assets using proprietary technology. Based in San Francisco, the company generates clean power through innovative geoscience methods, aiming to provide a dispatchable foundation for a 100% clean energy future.
Enzinc
Seed Round in 2022
Enzinc is an innovative company developing advanced rechargeable zinc-air batteries. Utilizing proprietary nano-sponge technology, Enzinc's batteries offer high energy density akin to lithium-ion batteries but at a cost comparable to lead acid batteries, making them safer and more affordable.
Kaleidoscope
Series A in 2022
Founded in 2016, Kaleidoscope designs, administers, and hosts branded scholarship and grant programs on a cloud-based marketplace. Its platform connects scholarship funders with qualified students, creating personalized, curated opportunities.
Koya Medical
Series B in 2022
Koya Medical, Inc. is a healthcare company based in Oakland, California, founded in 2018. The company specializes in developing innovative wearable therapeutic devices aimed at treating cancer-related chronic lymphedema and various venous diseases. Koya Medical's technology offers active compression therapy that enhances mobility and personalized care, addressing limitations commonly associated with traditional compression methods. Its sensor-based closed-loop system provides patient-specific patterned compression, enabling healthcare providers to effectively manage conditions like chronic edema and chronic venous insufficiency. Through its breakthrough treatments, Koya Medical seeks to transform the standard of care for individuals affected by these debilitating conditions.
Good Therapeutics
Series B in 2021
Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2016. The company specializes in developing innovative biotherapeutics and self-regulating drugs that provide therapeutic activity in a context-dependent manner. Their core technology involves designing allosterically-regulated proteins that can detect specific biomarkers and respond accordingly, activating therapeutic functions only when and where needed. This approach aims to enhance drug safety and efficacy by reducing systemic toxicity while maintaining therapeutic effectiveness. Currently, Good Therapeutics is primarily focused on applications within immuno-oncology, aiming to create safer and more effective treatment options that optimize patient outcomes.
Claros Technologies
Series A in 2021
Claros Technologies is an advanced materials company that develops safe and sustainable products with zero toxic waste. It strives to lead the industry towards a holistic approach to materials design and innovation.
It was founded in 2018 and is based in St Paul, Minnesota.
Source
Series C in 2020
Source is a developer and manufacturer of solar-powered devices that extract drinkable water from the atmosphere. Its hydro panel technology uses advanced materials science to pull water from even the driest conditions and mineralize it for delivery to taps, enabling clean water access for residential, commercial, industrial, and community use. The company was founded in 2014 and is headquartered in Scottsdale, Arizona.
Amplyx Pharmaceuticals
Series C in 2020
Amplyx Pharmaceuticals, Inc. is a small molecule drug development company focused on creating innovative therapies for debilitating and life-threatening diseases, particularly those affecting individuals with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in the development of oral and injectable anti-infective drugs, including antifungal agents designed to treat invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by incorporating a second small molecule. This strategy aims to provide effective treatment options for patients undergoing chemotherapy and other immunosuppressive therapies, ensuring they receive appropriate care both during hospitalization and after discharge.
Good Therapeutics
Series A in 2020
Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2016. The company specializes in developing innovative biotherapeutics and self-regulating drugs that provide therapeutic activity in a context-dependent manner. Their core technology involves designing allosterically-regulated proteins that can detect specific biomarkers and respond accordingly, activating therapeutic functions only when and where needed. This approach aims to enhance drug safety and efficacy by reducing systemic toxicity while maintaining therapeutic effectiveness. Currently, Good Therapeutics is primarily focused on applications within immuno-oncology, aiming to create safer and more effective treatment options that optimize patient outcomes.
Adarza BioSystems
Series D in 2020
Adarza BioSystems is an early-stage medical diagnostics company based in St. Louis, Missouri, that specializes in developing a rapid and label-free biological assay platform for clinical and point-of-care samples. Founded in 2008, the company utilizes its innovative arrayed imaging reflectometry technology to enable the simultaneous detection of hundreds of analytes from a single drop of fluid. This platform allows healthcare professionals to conduct sophisticated tests in a matter of minutes, ensuring high sensitivity and specificity in the detection of multiplexed proteins. Adarza BioSystems aims to enhance diagnostic capabilities, improving patient outcomes through quicker and more accurate testing.
Smart Wires
Series E in 2019
Founded in 2010, Smart Wires Inc. specializes in manufacturing and distributing modular power flow control products and grid optimization solutions for transmission organizations worldwide. Its solutions enhance grid reliability, facilitate renewable connections, resolve short-term issues, accelerate projects, minimize disruption, mitigate uncertainty, and improve power transfer capacity.
InterVene
Series B in 2019
InterVene is a medical device company focused on innovating treatments for chronic venous disease, particularly deep vein valve failure. The company develops catheter-based, non-implantable therapies designed to restore valvular competency in the deep veins affected by chronic venous insufficiency. Its BlueLeaf Endovenous Valve Formation System is described as a non-implantable solution to create new vein valves from the patient's own vein wall tissue, enabling minimally invasive treatment for conditions such as venous stasis ulcers and related symptoms. Founded in 2011 and based in South San Francisco, California, InterVene aims to improve valve function and blood flow in legs through catheter-based approaches that avoid implants.
Good Therapeutics
Series A in 2019
Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2016. The company specializes in developing innovative biotherapeutics and self-regulating drugs that provide therapeutic activity in a context-dependent manner. Their core technology involves designing allosterically-regulated proteins that can detect specific biomarkers and respond accordingly, activating therapeutic functions only when and where needed. This approach aims to enhance drug safety and efficacy by reducing systemic toxicity while maintaining therapeutic effectiveness. Currently, Good Therapeutics is primarily focused on applications within immuno-oncology, aiming to create safer and more effective treatment options that optimize patient outcomes.
Allakos
Series B in 2017
Allakos is a clinical-stage biopharmaceutical company developing antibody-based therapeutics targeting immunomodulatory receptors on immune effector cells. Its pipeline focuses on allergic, inflammatory, and proliferative diseases, with lead programs targeting Siglec-6 (AK006) and Siglec-8.
Fishpeople
Series B in 2017
Fishpeople Seafood is a food production company founded in 2012 and headquartered in Portland, Oregon. The company specializes in providing sustainable seafood products to grocery retailers, aiming to disrupt the traditional seafood industry with innovative offerings. Fishpeople Seafood's product range includes wild American salmon, tuna, crab, and cod, all sourced sustainably. By focusing on authentic fish meat alternatives, Fishpeople Seafood enables consumers to embrace healthier and more environmentally responsible eating habits. The company is recognized for its rapid growth and commitment to sustainability in the seafood market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.